Kyung Duk Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kyung Duk Park has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Hee Young Shin
Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea
6 shared publications - Hyoung Jin Kang
Department of Pediatrics, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
5 shared publications - Hyery Kim
Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea
4 shared publications - Ji Won Lee
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
4 shared publications - Byung-Kiu Park
Center for Pediatric Oncology, National Cancer Center, Goyang, South Korea
3 shared publications - Ho Joon Im
Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Korea
3 shared publications
Latest Publications
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (4) , e37
Erratum: Correction of Affiliations in the Article “Clinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma: a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study”
Lee JM, et al. J Korean Med Sci. 2021 Jan;36(4):e37. https://doi.org/10.3346/jkms.2021.36.e37
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (4) , e37
Open AccessErratum: Correction of Affiliations in the Article “Clinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma: a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study”
Lee JM, et al. J Korean Med Sci. 2021 Jan;36(4):e37. https://doi.org/10.3346/jkms.2021.36.e37
- Open Access
- 1 January 2020
- Published by XMLink in Journal of Korean Medical Science
- Vol. 35 (46) , e393
Clinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma: a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study
Lee JM, et al. J Korean Med Sci. 2020 Oct;35(46):e393. https://doi.org/10.3346/jkms.2020.35.e393
- 1 January 2020
- Published by XMLink in Journal of Korean Medical Science
- Vol. 35 (46) , e393
Open AccessClinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma: a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study
Lee JM, et al. J Korean Med Sci. 2020 Oct;35(46):e393. https://doi.org/10.3346/jkms.2020.35.e393
- Open Access
- 1 January 2020
- Published by XMLink in Journal of Korean Medical Science
- Vol. 35 (38)
New Paradigm of Pediatric Clinical Clerkship during the Epidemic of COVID-19
Lee YM, et al. J Korean Med Sci. 2020 Aug;35(38):e344. https://doi.org/10.3346/jkms.2020.35.e344
- 1 January 2020
- Published by XMLink in Journal of Korean Medical Science
- Vol. 35 (38)
Open AccessNew Paradigm of Pediatric Clinical Clerkship during the Epidemic of COVID-19
Lee YM, et al. J Korean Med Sci. 2020 Aug;35(38):e344. https://doi.org/10.3346/jkms.2020.35.e344
- Open Access
- 31 October 2018
- Published by The Korean Society of Pediatric Hematology-Oncology in Clinical Pediatric Hematology-Oncology
- Vol. 25 (2) , 97-101
Clinical Courses and Outcome of Newly Diagnosed Immune Thrombocytopenia in Infants
- 31 October 2018
- Published by The Korean Society of Pediatric Hematology-Oncology in Clinical Pediatric Hematology-Oncology
- Vol. 25 (2) , 97-101
Open AccessClinical Courses and Outcome of Newly Diagnosed Immune Thrombocytopenia in Infants
- Open Access
- 1 June 2017
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 153 (6) , 529-536
Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma
Infantile hemangioma (IH) is the most common tumor of infants and young children.1,2 Although small IH lesions typically do not cause problems, they often require treatment because of the site of occurrence and associated complications such as abnormal eye development or vision problems, airway obstruction, and bowel obstruction.3,4 Historically, steroids have been used as the primary treatment for IH.5,6 Steroids have been shown to be antiangiogenic in a number of in vitro settings and also have shown good therapeutic effects clinically. However, the use of steroids may lead to various complications including gastroesophageal reflux and growth disorders, although these complications are associated with long-term use and high dose.7 A type of anticancer drug or immunomodulator, interferon alfa, may be used for severe IH in cases where patients did not respond to steroids.8,9 However, interferon alfa also has several possible adverse effects, including fever, muscle pain, systemic myalgia, and in severe cases, liver damage, blood toxic effects, thyroid hormonal abnormality, and neurological and neurodevelopmental toxic effects.8 Because of concerns about these adverse effects, many guardians of pediatric patients prefer to wait rather than accept treatment.
- 1 June 2017
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 153 (6) , 529-536
Open AccessComparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma
Infantile hemangioma (IH) is the most common tumor of infants and young children.1,2 Although small IH lesions typically do not cause problems, they often require treatment because of the site of occurrence and associated complications such as abnormal eye development or vision problems, airway obstruction, and bowel obstruction.3,4 Historically, steroids have been used as the primary treatment for IH.5,6 Steroids have been shown to be antiangiogenic in a number of in vitro settings and also have shown good therapeutic effects clinically. However, the use of steroids may lead to various complications including gastroesophageal reflux and growth disorders, although these complications are associated with long-term use and high dose.7 A type of anticancer drug or immunomodulator, interferon alfa, may be used for severe IH in cases where patients did not respond to steroids.8,9 However, interferon alfa also has several possible adverse effects, including fever, muscle pain, systemic myalgia, and in severe cases, liver damage, blood toxic effects, thyroid hormonal abnormality, and neurological and neurodevelopmental toxic effects.8 Because of concerns about these adverse effects, many guardians of pediatric patients prefer to wait rather than accept treatment.
- Open Access
- 10 May 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-11
Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients
Owing to its narrow therapeutic range and high pharmacokinetic variability, optimal dosing for busulfan is important to minimise overexposure-related systemic toxicity and underexposure-related graft failure. Using global metabolomics, we investigated biomarkers for predicting busulfan exposure. We analysed urine samples obtained before busulfan administration from 59 paediatric patients divided into 3 groups classified by area under the busulfan concentration-time curve (AUC), i.e., low-, medium-, and high-AUC groups. In the high-AUC group, deferoxamine metabolites were detected. Phenylacetylglutamine and two acylcarnitines were significantly lower in the high-AUC group than in the low-AUC group. Deferoxamine, an iron-chelating agent that lowers serum ferritin levels, was detected in the high-AUC group, indicating that those patients had high ferritin levels. Therefore, in a retrospective study of 130 paediatric patients, we confirmed our hypothesis that busulfan clearance (dose/AUC) and serum ferritin level has a negative correlation (r = −0.205, P = 0.019). Ferritin, acylcarnitine, and phenylacetylglutamine are associated with liver damage, including free radical formation, deregulation of hepatic mitochondrial β-oxidation, and hyperammonaemia. Our findings reveal potential biomarkers predictive of busulfan exposure and suggest that liver function may affect busulfan exposure.
- 10 May 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-11
Open AccessPharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients
Owing to its narrow therapeutic range and high pharmacokinetic variability, optimal dosing for busulfan is important to minimise overexposure-related systemic toxicity and underexposure-related graft failure. Using global metabolomics, we investigated biomarkers for predicting busulfan exposure. We analysed urine samples obtained before busulfan administration from 59 paediatric patients divided into 3 groups classified by area under the busulfan concentration-time curve (AUC), i.e., low-, medium-, and high-AUC groups. In the high-AUC group, deferoxamine metabolites were detected. Phenylacetylglutamine and two acylcarnitines were significantly lower in the high-AUC group than in the low-AUC group. Deferoxamine, an iron-chelating agent that lowers serum ferritin levels, was detected in the high-AUC group, indicating that those patients had high ferritin levels. Therefore, in a retrospective study of 130 paediatric patients, we confirmed our hypothesis that busulfan clearance (dose/AUC) and serum ferritin level has a negative correlation (r = −0.205, P = 0.019). Ferritin, acylcarnitine, and phenylacetylglutamine are associated with liver damage, including free radical formation, deregulation of hepatic mitochondrial β-oxidation, and hyperammonaemia. Our findings reveal potential biomarkers predictive of busulfan exposure and suggest that liver function may affect busulfan exposure.
- Open Access
- 1 January 2017
- Published by XMLink in Journal of Korean Medical Science
- Vol. 32 (4) , 642-649
Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study
Koh KN, et al. J Korean Med Sci. 2017 Apr;32(4):642-649. https://doi.org/10.3346/jkms.2017.32.4.642
- 1 January 2017
- Published by XMLink in Journal of Korean Medical Science
- Vol. 32 (4) , 642-649
Open AccessOutcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study
Koh KN, et al. J Korean Med Sci. 2017 Apr;32(4):642-649. https://doi.org/10.3346/jkms.2017.32.4.642
- Open Access
- 19 November 2010
- Published by American Society of Hematology in Blood
- Vol. 116 (21) , 2060
Pharmacogenetic Study of Deferasirox, An Iron Chelating Agent
Abstract 2060 Transfusion associated iron overload induce systemic toxicity. Deferoxamine had been used to reduce iron induced toxicities by chelating iron but it is a short acting drug and needs parenteral administration. Recently, deferasirox, a more convenient long acting oral agent, has been introduced in clinical practice with promising efficacy. However, some patients experienced drug-related toxicities and could not tolerate it. As the deferasirox is known to be metabolized primarily by glucuronidation and excreted mainly into the feces, the effect and toxicity of deferasirox may be influenced by the variability of uridine diphosphate glycosyltransferases (UGTs) and ATP-binding cassette transporters (multi-drug resistance-associated protein 2 (MRP2) and breast cancer resistance protein (BCRP)) which are important for intestinal drug absorption and hepatic drug elimination. To predict toxicities and find optimal target population, we analyzed the genetic polymorphisms of UGT1A subfamily, MRP2 and BCRP among pediatric patients received deferasirox. Total 20 functional genetic polymorphisms including BCRP (34G>A, 8191C>T, 8825C>A), MRP2 (-1774delG, -24C>T), UGTA1 (-3279T>G, -39insTA, 211G>A, 686C>A), UGT1A3 (17A>G, 31T>C, 81G>A, 133C>T, 140T>C, 477A>G), UGT1A7 (387T>G, 391C>A, 392G>A, 622T>C), and UGT1A9 (-118insT) were analyzed in 98 patients who received deferasirox to reduce transfusion induced iron overload (ferritin > 1,000 ng/ml). The median age of patients was 9 years (1-23 years) and the diagnosis were acute leukemia in 23, lymphoma in 4, solid tumor in 63, aplastic anemia in 5, and other hematologic disease in 3. Drug-related toxicities were defined by overall, hepatotoxicity, renal toxicity, GI toxicity and skin toxicity using NCI-CTC 3.0. The associations of genetic variability on the drug-related toxicities were evaluated by logistic regression models for the risk of toxicities as well as Cox-proportional hazard models focusing on times until toxicities occurred. Patients received median 29.4 (range 17.9–34.1) mg/kg of deferasirox. Total 39 patients discontinued deferasirox owing to drug-related toxicities at median 56 (range 6–583) days after the administration and the cumulative incidence (CI) was 39.8%. The most frequent toxicity was increased AST/ALT over Grade 3 in 15 patients with CI 15.3%. GI toxicity, skin toxicity and renal toxicity occurred with CIs of 12.2% (N=12), 9.2% (N=9), and 5.1% (N=5), respectively. Patients carrying two MRP2 haplotypes containing -1774del and/or -24T had more 7-fold risk as well as 5-fold hazard of hepatotoxicity compared to patients with the wild-type allele (OR=7.05, 95% CI=1.77-28.11; HR=5.17, 95% CI=1.64-16.29). The UGT1A7 haplotypes containing reduced activity allele also increased the risk and hazard of renal toxicity although the number of patients with renal toxicity was small (OR=41.10, 95% CI=2.00-842.98; HR=87.64, 95% CI=3.61-2126.06). Other genetic polymorphisms were not associated with any drug-related toxicity. This finding suggests that functional genetic variants of enzymes to metabolize and transport deferasirox were associated with drug-related toxicities. Further study is warranted to confirm the results as the pharmacogenetic biomarkers of deferasirox.
- 19 November 2010
- Published by American Society of Hematology in Blood
- Vol. 116 (21) , 2060
Open AccessPharmacogenetic Study of Deferasirox, An Iron Chelating Agent
Abstract 2060 Transfusion associated iron overload induce systemic toxicity. Deferoxamine had been used to reduce iron induced toxicities by chelating iron but it is a short acting drug and needs parenteral administration. Recently, deferasirox, a more convenient long acting oral agent, has been introduced in clinical practice with promising efficacy. However, some patients experienced drug-related toxicities and could not tolerate it. As the deferasirox is known to be metabolized primarily by glucuronidation and excreted mainly into the feces, the effect and toxicity of deferasirox may be influenced by the variability of uridine diphosphate glycosyltransferases (UGTs) and ATP-binding cassette transporters (multi-drug resistance-associated protein 2 (MRP2) and breast cancer resistance protein (BCRP)) which are important for intestinal drug absorption and hepatic drug elimination. To predict toxicities and find optimal target population, we analyzed the genetic polymorphisms of UGT1A subfamily, MRP2 and BCRP among pediatric patients received deferasirox. Total 20 functional genetic polymorphisms including BCRP (34G>A, 8191C>T, 8825C>A), MRP2 (-1774delG, -24C>T), UGTA1 (-3279T>G, -39insTA, 211G>A, 686C>A), UGT1A3 (17A>G, 31T>C, 81G>A, 133C>T, 140T>C, 477A>G), UGT1A7 (387T>G, 391C>A, 392G>A, 622T>C), and UGT1A9 (-118insT) were analyzed in 98 patients who received deferasirox to reduce transfusion induced iron overload (ferritin > 1,000 ng/ml). The median age of patients was 9 years (1-23 years) and the diagnosis were acute leukemia in 23, lymphoma in 4, solid tumor in 63, aplastic anemia in 5, and other hematologic disease in 3. Drug-related toxicities were defined by overall, hepatotoxicity, renal toxicity, GI toxicity and skin toxicity using NCI-CTC 3.0. The associations of genetic variability on the drug-related toxicities were evaluated by logistic regression models for the risk of toxicities as well as Cox-proportional hazard models focusing on times until toxicities occurred. Patients received median 29.4 (range 17.9–34.1) mg/kg of deferasirox. Total 39 patients discontinued deferasirox owing to drug-related toxicities at median 56 (range 6–583) days after the administration and the cumulative incidence (CI) was 39.8%. The most frequent toxicity was increased AST/ALT over Grade 3 in 15 patients with CI 15.3%. GI toxicity, skin toxicity and renal toxicity occurred with CIs of 12.2% (N=12), 9.2% (N=9), and 5.1% (N=5), respectively. Patients carrying two MRP2 haplotypes containing -1774del and/or -24T had more 7-fold risk as well as 5-fold hazard of hepatotoxicity compared to patients with the wild-type allele (OR=7.05, 95% CI=1.77-28.11; HR=5.17, 95% CI=1.64-16.29). The UGT1A7 haplotypes containing reduced activity allele also increased the risk and hazard of renal toxicity although the number of patients with renal toxicity was small (OR=41.10, 95% CI=2.00-842.98; HR=87.64, 95% CI=3.61-2126.06). Other genetic polymorphisms were not associated with any drug-related toxicity. This finding suggests that functional genetic variants of enzymes to metabolize and transport deferasirox were associated with drug-related toxicities. Further study is warranted to confirm the results as the pharmacogenetic biomarkers of deferasirox.